Titan Pharmaceuticals, Inc. (de)
TTNP
Market Cap$3.43M
Close$
$3.15
40.6% downside
Current Fair Value
40.6% downsideOvervalued by 40.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.43 Million |
|---|---|
| Enterprise Value | $597,378.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.23 |
| Beta | 1.28 |
| Outstanding Shares | 914,234 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.73 |
|---|---|
| PEG | -0.58 |
| Price to Sales | - |
| Price to Book Ratio | 2.65 |
| Enterprise Value to Revenue | 7.38 |
| Enterprise Value to EBIT | -0.1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Titan Pharmaceuticals, Inc. (de)
12 employeesTitan Pharmaceuticals, Inc., based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potentia...